Effect of Methylprednisolone in acute spinal cord injury

Comparing the efficacy of the intrathecal with intravenous Methylprednisolone administration in outcome of patients with acute thoracolumbar spinal cord injury (SCI)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190116042374N1

Enrollment

Registered

2019-02-04

Start date

2018-10-22

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A 48-hour regimen with methyl prednisolone in patients with acute spinal cord injuries significantly improves neurological symptoms in patients..

Interventions

Intervention 1: Intervention group: Traumatic patients with acute spinal cord injuries injected intrathecal Methylprednisolone acetate with a dose of 1 mg per kg and this treatment protocol will be re

Eligibility

Sex/Gender

All

Age

13 Years to No maximum

Inclusion criteria

Inclusion criteria: All traumatic patients with acute thoracolumbar spinal cord injury Age over 13 years

Exclusion criteria

Exclusion criteria: Patients with nerve spinal cord injury or single injury Cauda equina Damage after injury with bullets Pregnant patients Patients receiving steroids for other reasons Patients under 13 years of age Patients with a history of receiving 100 mg of Methylprednisolone or a diet equal to it Diabetic patients Patients with immunodeficiency Patients Needing Emergency Surgery Loss of consciousness LP contraindications and any traumatic lesions of the brain

Design outcomes

Primary

Measure	Time frame
The evaluation of peroxidation metabolites (TAC) total antioxidant capacity (MDA) and malondialdehyde (MDA), which indicates the inflammatory status of the spinal cord, as well as sensory and motor status assessment based on ASIA and FRANKL grading at discharge. Timepoint: Patients will undergo a re-examination and assessment of sensory and motor status in three intervals at the time of discharge (day 7-10) of the sixth week (day 42-49) and the sixth month (day 180-150)after treatment. On day 1 and 4 of admission, total antioxidant capacity and malondialdehyd (TAC and MDA)is measured. Method of measurement: The sensory and motor status of the patient is measured at each turn with the examination and total antioxidant capacity and malondialdehyd metabolites in the laboratory by the device.	—

Measure

Time frame

The evaluation of peroxidation metabolites (TAC) total antioxidant capacity (MDA) and malondialdehyde (MDA), which indicates the inflammatory status of the spinal cord, as well as sensory and motor status assessment based on ASIA and FRANKL grading at discharge. Timepoint: Patients will undergo a re-examination and assessment of sensory and motor status in three intervals at the time of discharge (day 7-10) of the sixth week (day 42-49) and the sixth month (day 180-150)after treatment. On day 1 and 4 of admission, total antioxidant capacity and malondialdehyd (TAC and MDA)is measured. Method of measurement: The sensory and motor status of the patient is measured at each turn with the examination and total antioxidant capacity and malondialdehyd metabolites in the laboratory by the device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Meshkini

Tabriz University of Medical Sciences

Meshkinia@tbzmed.ac.ir+98 41 3334 7058

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026